If you liked this article you might like

New Setback for Sanofi's Lantus Increases Need for M&A
Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition
These 5 Biotech Stocks Are Ready for a Volatility Break
BioMarin (BMRN) Stock Surges on Takeover Speculation